CR20200457A - Proceso para la preparación de estumaladores de guanilato ciclasa soluble - Google Patents
Proceso para la preparación de estumaladores de guanilato ciclasa solubleInfo
- Publication number
- CR20200457A CR20200457A CR20200457A CR20200457A CR20200457A CR 20200457 A CR20200457 A CR 20200457A CR 20200457 A CR20200457 A CR 20200457A CR 20200457 A CR20200457 A CR 20200457A CR 20200457 A CR20200457 A CR 20200457A
- Authority
- CR
- Costa Rica
- Prior art keywords
- guanylate cyclase
- soluble guanylate
- preparing soluble
- cyclase stimulators
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p> </p> <p>La invención se relaciona con nuevos métodos para preparar compuestos 1,2,4-triazol 3-sustituidos como estimulantes de sGC y sus precursores de síntesis.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639642P | 2018-03-07 | 2018-03-07 | |
| PCT/US2019/021076 WO2019173548A1 (en) | 2018-03-07 | 2019-03-07 | Process for preparing soluble guanylate cyclase stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200457A true CR20200457A (es) | 2020-11-23 |
Family
ID=65904546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200457A CR20200457A (es) | 2018-03-07 | 2019-03-07 | Proceso para la preparación de estumaladores de guanilato ciclasa soluble |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11466014B2 (es) |
| EP (1) | EP3762390A1 (es) |
| JP (1) | JP7406692B2 (es) |
| KR (1) | KR102926111B1 (es) |
| CN (1) | CN111836811B (es) |
| AU (1) | AU2019231721B2 (es) |
| BR (1) | BR112020017999A2 (es) |
| CA (1) | CA3092680A1 (es) |
| CL (2) | CL2020002283A1 (es) |
| CO (1) | CO2020012492A2 (es) |
| CR (1) | CR20200457A (es) |
| EA (1) | EA202092108A1 (es) |
| IL (1) | IL276852B2 (es) |
| MX (2) | MX2020009185A (es) |
| PE (1) | PE20211413A1 (es) |
| PH (1) | PH12020551389A1 (es) |
| SG (1) | SG11202008592UA (es) |
| TW (1) | TWI812679B (es) |
| WO (1) | WO2019173548A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019231721B2 (en) | 2018-03-07 | 2024-06-27 | Tisento Therapeutics Inc. | Process for preparing soluble guanylate cyclase stimulators |
| WO2021195403A1 (en) | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004048350A2 (en) * | 2002-11-28 | 2004-06-10 | Astrazeneca Ab | Oxazolidinones as antibacterial agents |
| WO2015187470A1 (en) | 2014-06-04 | 2015-12-10 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| CA2961489A1 (en) * | 2014-09-17 | 2016-03-24 | Glen Robert RENNIE | Sgc stimulators |
| EP3872080B1 (en) * | 2016-09-02 | 2023-08-16 | Cyclerion Therapeutics, Inc. | Fused bicyclic sgc stimulators |
| AU2019231721B2 (en) | 2018-03-07 | 2024-06-27 | Tisento Therapeutics Inc. | Process for preparing soluble guanylate cyclase stimulators |
-
2019
- 2019-03-07 AU AU2019231721A patent/AU2019231721B2/en active Active
- 2019-03-07 SG SG11202008592UA patent/SG11202008592UA/en unknown
- 2019-03-07 CR CR20200457A patent/CR20200457A/es unknown
- 2019-03-07 EP EP19713257.4A patent/EP3762390A1/en active Pending
- 2019-03-07 MX MX2020009185A patent/MX2020009185A/es unknown
- 2019-03-07 KR KR1020207028166A patent/KR102926111B1/ko active Active
- 2019-03-07 US US16/976,249 patent/US11466014B2/en active Active
- 2019-03-07 CN CN201980017653.1A patent/CN111836811B/zh active Active
- 2019-03-07 BR BR112020017999-0A patent/BR112020017999A2/pt unknown
- 2019-03-07 TW TW108107663A patent/TWI812679B/zh active
- 2019-03-07 WO PCT/US2019/021076 patent/WO2019173548A1/en not_active Ceased
- 2019-03-07 PE PE2020001346A patent/PE20211413A1/es unknown
- 2019-03-07 JP JP2020546498A patent/JP7406692B2/ja active Active
- 2019-03-07 CA CA3092680A patent/CA3092680A1/en active Pending
- 2019-03-07 IL IL276852A patent/IL276852B2/en unknown
- 2019-03-07 EA EA202092108A patent/EA202092108A1/ru unknown
-
2020
- 2020-09-03 CL CL2020002283A patent/CL2020002283A1/es unknown
- 2020-09-03 MX MX2022015309A patent/MX2022015309A/es unknown
- 2020-09-04 PH PH12020551389A patent/PH12020551389A1/en unknown
- 2020-10-06 CO CONC2020/0012492A patent/CO2020012492A2/es unknown
-
2021
- 2021-02-04 CL CL2021000302A patent/CL2021000302A1/es unknown
-
2022
- 2022-09-28 US US17/954,725 patent/US12054489B2/en active Active
-
2024
- 2024-12-20 US US18/990,550 patent/US20250270219A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL276852A (en) | 2020-10-29 |
| CA3092680A1 (en) | 2019-09-12 |
| PE20211413A1 (es) | 2021-08-02 |
| MX2022015309A (es) | 2023-01-11 |
| PH12020551389A1 (en) | 2021-09-13 |
| US20250270219A1 (en) | 2025-08-28 |
| US20230128639A1 (en) | 2023-04-27 |
| US12054489B2 (en) | 2024-08-06 |
| EA202092108A1 (ru) | 2021-03-04 |
| US20210032254A1 (en) | 2021-02-04 |
| CN111836811B (zh) | 2024-11-22 |
| MX2020009185A (es) | 2020-10-08 |
| TWI812679B (zh) | 2023-08-21 |
| JP2021515018A (ja) | 2021-06-17 |
| US11466014B2 (en) | 2022-10-11 |
| CN111836811A (zh) | 2020-10-27 |
| AU2019231721A1 (en) | 2020-10-22 |
| KR20200128707A (ko) | 2020-11-16 |
| CL2021000302A1 (es) | 2021-06-18 |
| CL2020002283A1 (es) | 2020-11-27 |
| AU2019231721B2 (en) | 2024-06-27 |
| JP7406692B2 (ja) | 2023-12-28 |
| WO2019173548A1 (en) | 2019-09-12 |
| IL276852B2 (en) | 2024-06-01 |
| SG11202008592UA (en) | 2020-10-29 |
| TW202000668A (zh) | 2020-01-01 |
| EP3762390A1 (en) | 2021-01-13 |
| CO2020012492A2 (es) | 2020-10-30 |
| IL276852B1 (en) | 2024-02-01 |
| BR112020017999A2 (pt) | 2020-12-22 |
| KR102926111B1 (ko) | 2026-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909186YA (en) | Triazole silane compound, method for synthesizing said compound and use thereof | |
| PH12019502138A1 (en) | Compounds and compositions for treating hematological disorders | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
| MY199348A (en) | Process for preparing optically active 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds | |
| MX2020006185A (es) | Proceso para la preparacion de derivados de quinolina. | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| SG11201906688VA (en) | Novel ester compounds, method for the production thereof and use thereof | |
| MX2020002449A (es) | Nuevos compuestos heterociclicos fungicidas. | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| JOP20200256A1 (ar) | طريقة لتحضير 1، 2، 4-تريازولون يحمل ثلاثة بدائل في المواقع 2، 4، 5 | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| PH12020550592A1 (en) | Process for producing herbicidal pyridazinone compounds | |
| ZA201805790B (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof | |
| MX2020006370A (es) | Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas. | |
| WO2018039077A8 (en) | Therapeutic compounds | |
| PH12020551389A1 (en) | Process for preparing soluble guanylate cyclase stimulators | |
| ZA201904371B (en) | Compounds and compositions | |
| WO2016164295A3 (en) | Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors | |
| UA117524C2 (uk) | Стимулятори рослин, їх застосування та спосіб стимуляції рослин | |
| EP4013416B8 (en) | Process for preparing 1,4-dihydro-4-oxoquinoline-2-carboxylates and 4-aminoquinoline compounds therefrom | |
| WO2017046816A3 (en) | Process for the preparation of derivatives of benzodioxole | |
| AU2019248350A8 (en) | Process for making sarecycline hydrochloride | |
| PH12021552389A1 (en) | Quinoline derivatives and their use for the treatment of cancer |